Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population

Table 3

(a) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit¹. (b) Cost categories breakdown per patient per month (PPPM) by demographic characteristics, IV drug, and number of drugs administered per visit¹.

(a)

Category	No. of patients	No. of visits	Total		IV drug		IV administration		Other visit-related services
			Average costs ($)	%	Average costs ($)	%	Average costs ($)	%	Average costs ($)	%
Total	1,228	13,583	2,427.33	100.0%	1,449.85	59.7%	399.42	16.5%	578.06	23.8%
Age
Less than 25	117	1,944	1,117.32	100.0%	462.60	41.4%	314.53	28.1%	340.19	30.4%
25 to 39	152	2,001	2,228.42	100.0%	1,276.28	57.3%	447.07	20.1%	505.07	22.7%
40 to 54	316	3,471	2,632.44	100.0%	1,531.81	58.2%	435.10	16.5%	665.52	25.3%
55 to 64	345	3,351	3,292.29	100.0%	2,057.09	62.5%	457.14	13.9%	778.06	23.6%
Greater than 64	298	2,816	2,190.91	100.0%	1,431.09	65.3%	311.49	14.2%	448.33	20.5%
Gender^2
Female	289	3,367	2,149.91	100.0%	1,282.05	59.6%	341.70	15.9%	526.16	24.5%
Male	295	3,617	2,082.48	100.0%	1,162.35	55.8%	360.57	17.3%	559.56	26.9%
Region
Midwest	240	2,653	2,471.90	100.0%	1,485.45	60.1%	424.76	17.2%	561.69	22.7%
Northeast	41	342	2,240.14	100.0%	1,348.44	60.2%	391.31	17.5%	500.39	22.3%
South	610	7,112	2,140.51	100.0%	1,166.50	54.5%	373.68	17.5%	600.33	28.0%
Southwest	107	1,064	1,675.80	100.0%	1,026.85	61.3%	308.40	18.4%	340.56	20.3%
West	230	2,412	3,582.08	100.0%	2,447.14	68.3%	488.75	13.6%	646.19	18.0%
Insurance type^3
Managed care	622	6,874	2,936.17	100.0%	1,783.86	60.8%	504.22	17.2%	648.10	22.1%
Medicare	283	2,763	1,879.52	100.0%	1,182.80	62.9%	271.84	14.5%	424.88	22.6%
Medicare HMO	24	251	1,543.22	100.0%	880.70	57.1%	241.51	15.6%	421.01	27.3%
Medicaid	67	787	859.31	100.0%	344.74	40.1%	91.61	10.7%	422.96	49.2%
Medicaid HMO	10	145	709.35	100.0%	334.71	47.2%	185.94	26.2%	188.70	26.6%
Indemnity	68	1,036	2,199.25	100.0%	1,359.22	61.8%	371.24	16.9%	468.80	21.3%
Other^4	154	1,727	2,402.50	100.0%	1,281.98	53.4%	384.41	16.0%	736.11	30.6%
IV drug (for mSTS)^5
Gemcitabine-based	429	3,315	3,302.95	100.0%	2,447.16	74.1%	358.70	10.9%	497.09	15.0%
Anthracycline-based	434	2,005	2,344.63	100.0%	1,024.02	43.7%	479.23	20.4%	841.38	35.9%
Alkylating-agents-based	424	3,772	1,469.59	100.0%	474.53	32.3%	433.81	29.5%	561.25	38.2%
Angiogenesis inhibitors	58	374	5,249.94	100.0%	4,291.45	81.7%	301.03	5.7%	657.47	12.5%
Taxane-based	172	1,123	2,184.18	100.0%	1,323.34	60.6%	409.22	18.7%	451.62	20.7%
Other	352	2,994	2,458.42	100.0%	1,552.03	63.1%	356.33	14.5%	550.06	22.4%
Number of administered IV drugs^6
One	998	8,016	1,855.27	100.0%	1,007.91	54.3%	304.23	16.4%	543.13	29.3%
Two	680	4,336	3,423.98	100.0%	2,348.01	68.6%	481.76	14.1%	594.21	17.4%
Three	161	1,049	2,515.14	100.0%	1,058.61	42.1%	693.36	27.6%	763.17	30.3%
Four	47	182	3,372.39	100.0%	1,771.78	52.5%	935.96	27.8%	664.65	19.7%

3

Category	No. of patients	No. of months	Total		IV drug		IV administration		Other visit-related services
			Average costs ($)	%	Average costs ($)	%	Average costs ($)	%	Average costs ($)	%
Total	1,228	6,025.0	5,467.61	100.0%	3,268.45	59.8%	899.57	16.5%	1,299.60	23.8%
Age
Less than 25	117	623.3	3,476.65	100.0%	1,442.50	41.5%	978.12	28.1%	1,056.03	30.4%
25 to 39	152	836.2	5,338.35	100.0%	3,054.94	57.2%	1,070.62	20.1%	1,212.80	22.7%
40 to 54	316	1,513.3	6,030.91	100.0%	3,511.16	58.2%	997.38	16.5%	1,522.37	25.2%
55 to 64	345	1,650.8	6,686.45	100.0%	4,181.94	62.5%	928.28	13.9%	1,576.23	23.6%
Greater than 64	298	1,401.4	4,386.23	100.0%	2,869.85	65.4%	623.09	14.2%	893.29	20.4%
Gender^2
Female	289	1,588.8	4,544.31	100.0%	2,712.88	59.7%	721.32	15.9%	1,110.11	24.4%
Male	295	1,563.7	4,819.57	100.0%	2,689.15	55.8%	835.49	17.3%	1,294.93	26.9%
Region
Midwest	240	1,040.6	6,289.83	100.0%	3,784.40	60.2%	1,079.88	17.2%	1,425.55	22.7%
Northeast	41	207.8	3,687.44	100.0%	2,219.64	60.2%	644.12	17.5%	823.67	22.3%
South	610	3,200.9	4,753.24	100.0%	2,590.95	54.5%	830.59	17.5%	1,331.70	28.0%
Southwest	107	434.6	4,106.94	100.0%	2,531.00	61.6%	754.76	18.4%	821.18	20.0%
West	230	1,141.2	7,563.95	100.0%	5,170.11	68.4%	1,030.27	13.6%	1,363.58	18.0%
Insurance type^3
Managed care	622	3,088.9	6,532.36	100.0%	3,971.37	60.8%	1,120.58	17.2%	1,440.41	22.1%
Medicare	283	1,374.0	3,764.41	100.0%	2,374.73	63.1%	544.94	14.5%	844.73	22.4%
Medicare HMO	24	113.4	3,415.78	100.0%	1,949.36	57.1%	534.56	15.6%	931.86	27.3%
Medicaid	67	375.7	1,804.71	100.0%	722.61	40.0%	196.05	10.9%	886.05	49.1%
Medicaid HMO	10	37.9	2,716.27	100.0%	1,281.66	47.2%	712.02	26.2%	722.59	26.6%
Indemnity	68	365.1	6,232.59	100.0%	3,853.04	61.8%	1,051.79	16.9%	1,327.76	21.3%
Other^4	154	670.0	6,191.80	100.0%	3,305.31	53.4%	991.86	16.0%	1,894.63	30.6%
IV drug (for mSTS)
Gemcitabine-based	429	1,577.9	7,021.77	100.0%	5,208.74	74.2%	761.17	10.8%	1,051.86	15.0%
Anthracycline-based	434	1,243.0	3,752.46	100.0%	1,629.15	43.4%	768.24	20.5%	1,355.07	36.1%
Alkylating-agents-based	424	1,221.5	4,753.73	100.0%	1,559.65	32.8%	1,365.87	28.7%	1,828.21	38.5%
Angiogenesis inhibitors	58	321.6	7,532.36	100.0%	6,191.35	82.2%	460.33	6.1%	880.67	11.7%
Taxane-based	172	575.0	4,253.79	100.0%	2,563.94	60.3%	802.76	18.9%	887.08	20.9%
Other^5	352	1,086.0	6,006.84	100.0%	3,755.13	62.5%	907.76	15.1%	1,343.95	22.4%
Number of administered IV drugs^6
One	998	2,492.2	3,950.35	100.0%	2,105.69	53.3%	610.28	15.4%	1,234.38	31.2%
Two	680	2,781.1	6,616.14	100.0%	4,463.78	67.5%	954.84	14.4%	1,197.52	18.1%
Three	161	514.1	6,725.12	100.0%	2,888.23	42.9%	1,631.79	24.3%	2,205.10	32.8%
Four	47	237.6	5,218.13	100.0%	2,296.07	44.0%	1,702.72	32.6%	1,219.34	23.4%

1: Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.